Anemia Clinical Trials

Find Anemia Clinical Trials Near You

Safety and Efficacy of Combination Therapy (Danazol + Prednisolone + Thalidomide) in Thalidomide-Refractory Transfusion-Dependent β-Thalassemia Patients: A Prospective Randomized Controlled Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study will compare two treatments for children with beta-thalassemia who need regular blood transfusions and have not responded well to thalidomide. One group will continue thalidomide alone. The other group will receive thalidomide plus danazol and prednisolone. The study will check whether the combination treatment reduces the need for blood transfusions, raises hemoglobin levels, and is safe. About 172 children aged 5 to 15 will be assigned by chance to one of the two groups. They will be followed for 9 to 12 months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 15
Healthy Volunteers: f
View:

• Age 5 to 15 years with confirmed transfusion-dependent beta-thalassemia major.

• Documented non-response to adequately dosed thalidomide therapy for at least 6 months.

• Pre-transfusion hemoglobin less than 9.0 g/dL with continued transfusion dependence (more than 2 units per month).

• Adequate baseline clinical and laboratory assessment for safe study treatment.

• Stable transfusion and iron-chelation regimen according to the protocol.

• Written informed consent from parent/legal guardian and age-appropriate assent from the participant, with willingness to comply with study procedures and follow-up.

Locations
Other Locations
Pakistan
Pak International Medical College
RECRUITING
Peshawar
Contact Information
Primary
Syeda Nayab Imtiaz, MBBS
dr.nayabimtiaz@hotmail.com
+923369966014
Backup
Gulab Fatima Rani, MBBS
ranigulabfatima@gmail.com
+923357438822
Time Frame
Start Date: 2026-10-12
Estimated Completion Date: 2027-05-20
Participants
Target number of participants: 172
Treatments
Experimental: Thalidomide plus Danazol plus Prednisolone
In this treatment regimen, Thalidomide and Danazol are administered at a dosage of 100 mg orally three times daily for 30 days each cycle. Prednisolone is given at a dosage of 5 mg orally twice daily for 10 days each month. Supportive care includes Famotidine, folic acid, and vitamin B12. This treatment plan is continued for a duration of 9 to 12 months.
Active_comparator: Thalidomide Monotherapy
Thalidomide should be taken orally at a dose of 1 to 5 mg/kg at night, with dosage titrated upward every 2 to 4 weeks based on response and tolerance. Clopidogrel and aspirin should be taken together for thromboprophylaxis. This regimen should continue for 9 to 12 months.
Sponsors
Collaborators: Pak International Medical College and Hospital, Peshawar, Peshawar General Hospital
Leads: Khyber Medical University Peshawar

This content was sourced from clinicaltrials.gov

Similar Clinical Trials